Directorate Change
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dan Levangie, Non-Executive Director has stepped down from the Board of Renalytix, effective immediately, following the General Meeting today.
James McCullough, CEO of Renalytix plc, commented: "We would like to express our gratitude to Dan for all of his contributions to Renalytix during a very significant period for the business. Dan's counsel through these past years has been invaluable as we have conducted a successful turn-around and refinancing of Renalytix and expanded our commercial introduction of KidneyIntelX for early prognosis of chronic kidney disease."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.